# Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis

> **NCT01486524** · — · UNKNOWN · sponsor: **Sirius Genomics Inc.** · enrollment: 3000 (estimated)

## Conditions studied

- Severe Sepsis
- Septic Shock

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01486524
- **Lead sponsor:** Sirius Genomics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-10
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2011-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01486524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01486524, "Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01486524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*